LENG9 Inhibitors
LENG9 inhibitors pertain to a category of chemical compounds that indirectly affect the activity of LENG9 by interacting with signaling pathways or cellular processes that LENG9 is involved in. These inhibitors do not target LENG9 directly but can alter its functional state by modulating the activity of proteins and enzymes that interact with or regulate LENG9.
Staurosporine is known for its potent inhibition of protein kinases such as PKC. This inhibition can have a cascading effect on various signaling pathways within the cell. If LENG9's activity is modulated by a kinase that Staurosporine inhibits, then the functional state of LENG9 could be affected as a consequence of this inhibition.
SEE ALSO...
Items 11 to 12 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö6983 is a more selective pan-PKC inhibitor than staurosporine, with similar effects on PKC-mediated signaling. By inhibiting PKC, it can decrease the phosphorylation and activity of substrates within this pathway, possibly including LENG9 if PKC is involved in its regulation. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is a selective FGFR1 and FGFR3 tyrosine kinase inhibitor. Although FGFR signaling should be avoided, this compound's inhibition of FGFR-mediated pathways could potentially reduce the activation of downstream signaling cascades that might regulate LENG9's activity. | ||||||